Issue of Share Options

RNS Number : 7902I

Diaceutics PLC

06 April 2020

 

Diaceutics PLC

("Diaceutics" or the "Company")

Issue of Share Options

Diaceutics PLC (AIM: DXRX), the diagnostic commercialisation company, announces the issuance of share options over ordinary shares of 0.2p each in the Company ("Share Options") to certain Directors, members of the Company's senior management team and other key staff, pursuant to the Company's Employee Share Option Plan ("ESOP") established at the time of the Company's admission to AIM. These awards are made in accordance with the Company's long term incentive plan.

Share Options were granted as follows:

Name	Number of Share Options granted	Total no. of ordinary shares under option post grant	% of existing issued share capital	Grant date
Peter Keeling, CEO	180,000	180,000	0.26%	3 April 2020
Philip White CFO	180,000	180,000	0.26%	3 April 2020
Ryan Keeling CIO	180,000	180,000	0.26%	3 April 2020
Damian Thornton COO and PDMR	94,304	98,504	0.14%	3 April 2020
Jordan Clark CCO and PDMR	67,714	71,914	0.10%	3 April 2020
Susanne Munksted PDMR	62,272	66,472	0.10%	3 April 2020
Other employees (72 persons with no individual in excess of 45,000 Share Options)	665,955	825,555	1.19%	No later than 20 April 2020

The Share Options vest in full after three years following date of grant. The exercise price of the Share Options is 126.5p per share which has been calculated by using the average mid-market closing price over the past five business days.

Following the grant the total number of share options outstanding is 1,602,444, representing approximately 2.3% of the Company's current issued share capital of 69,583,100.

Enquiries:

Diaceutics PLC	www.diaceutics.com
Peter Keeling, Chief Executive Officer	via Walbrook PR
Philip White, Chief Financial Officer
Cenkos Securities plc (Nominated adviser and broker)			[phone]
Callum Davidson / Giles Balleny
Michael Johnson (Sales)
Walbrook PR	Tel: [phone] or [e-mail]
Anna Dunphy		Mob: [phone]
Paul McManus		Mob: [phone]

About Diaceutics

Diaceutics PLC is the diagnostic commercialisation company for global pharmaceutical companies. The Company, quoted on the Alternative Investment Market (AIM) of the London Stock Exchange, is enabling pharma to accelerate their market penetration and achieve a better return on precision medicine therapies by helping them to revolutionise patient testing.  By generating insights from its data lake of clinical laboratory testing data and other data, Diaceutics helps pharma understand and leverage the diagnostic landscape through initiatives that improve patient testing, leading to better treatment outcomes. The Company works with more than 35 global pharmaceutical companies across hundreds of precision medicine projects. The Company employs a leading global group of experts from the laboratory, diagnostic and pharmaceutical industries.  www.diaceutics.com

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014
1	Details of the person discharging managerial responsibilities/person closely associated
a.	Name	Peter Keeling
2	Reason for notification
a.	Position/Status	Chief Executive Officer
b.	Initial notification/ Amendment	Initial
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a.	Name	Diaceutics PLC
b.	LEI	213800VEWQBB39ZB8J81
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a.	Description of the financial instrument, type of instrument Identification Code	Options over new ordinary shares of 0.2 p each ISIN:  GB00BJQTGV64
b.	Nature of the transaction	Grant of share options
c.	Price(s) and volume(s)
			Price(s)	Volume(s)
			Exercise price of 126.5p per share	180,000
e.	Date of the transaction	3 April 2020
f.	Place of the transaction	Outside a trading venue

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014
1	Details of the person discharging managerial responsibilities/person closely associated
a.	Name	Philip White
2	Reason for notification
a.	Position/Status	Chief Financial Officer
b.	Initial notification/ Amendment	Initial
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a.	Name	Diaceutics PLC
b.	LEI	213800VEWQBB39ZB8J81
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a.	Description of the financial instrument, type of instrument Identification Code	Options over new ordinary shares of 0.2 p each ISIN:  GB00BJQTGV64
b.	Nature of the transaction	Grant of share options
c.	Price(s) and volume(s)
			Price(s)	Volume(s)
			Exercise price of 126.5p per share	180,000
e.	Date of the transaction	3 April 2020
f.	Place of the transaction	Outside a trading venue

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014
1	Details of the person discharging managerial responsibilities/person closely associated
a.	Name	Ryan Keeling
2	Reason for notification
a.	Position/Status	Chief Information Officer
b.	Initial notification/ Amendment	Initial
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a.	Name	Diaceutics PLC
b.	LEI	213800VEWQBB39ZB8J81
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a.	Description of the financial instrument, type of instrument Identification Code	Options over new ordinary shares of 0.2 p each ISIN:  GB00BJQTGV64
b.	Nature of the transaction	Grant of share options
c.	Price(s) and volume(s)
			Price(s)	Volume(s)
			Exercise price of 126.5p per share	180,000
e.	Date of the transaction	3 April 2020
f.	Place of the transaction	Outside a trading venue

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014
1	Details of the person discharging managerial responsibilities/person closely associated
a.	Name	Damian Thornton
2	Reason for notification
a.	Position/Status	Chief Operating Officer
b.	Initial notification/ Amendment	Initial
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a.	Name	Diaceutics PLC
b.	LEI	213800VEWQBB39ZB8J81
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a.	Description of the financial instrument, type of instrument Identification Code	Options over new ordinary shares of 0.2 p each ISIN:  GB00BJQTGV64
b.	Nature of the transaction	Grant of share options
c.	Price(s) and volume(s)
			Price(s)	Volume(s)
			Exercise price of 126.5p per share	94,304
e.	Date of the transaction	3 April 2020
f.	Place of the transaction	Outside a trading venue

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014
1	Details of the person discharging managerial responsibilities/person closely associated
a.	Name	Jordan Clark
2	Reason for notification
a.	Position/Status	Chief Technology Officer
b.	Initial notification/ Amendment	Initial
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a.	Name	Diaceutics PLC
b.	LEI	213800VEWQBB39ZB8J81
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a.	Description of the financial instrument, type of instrument Identification Code	Options over new ordinary shares of 0.2 p each ISIN:  GB00BJQTGV64
b.	Nature of the transaction	Grant of share options
c.	Price(s) and volume(s)
			Price(s)	Volume(s)
			Exercise price of 126.5p per share	67,714
e.	Date of the transaction	3 April 2020
f.	Place of the transaction	Outside a trading venue

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014
1	Details of the person discharging managerial responsibilities/person closely associated
a.	Name	Susanne Munksted
2	Reason for notification
a.	Position/Status	Managing Director and PDMR
b.	Initial notification/ Amendment	Initial
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a.	Name	Diaceutics PLC
b.	LEI	213800VEWQBB39ZB8J81
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a.	Description of the financial instrument, type of instrument Identification Code	Options over new ordinary shares of 0.2 p each ISIN:  GB00BJQTGV64
b.	Nature of the transaction	Grant of share options
c.	Price(s) and volume(s)
			Price(s)	Volume(s)
			Exercise price of 126.5p per share	62,272
e.	Date of the transaction	3 April 2020
f.	Place of the transaction	Outside a trading venue

 

END

 

 

DSHZZGGDDFVGGZM